Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2015

View Archived Issues

Novel synthetic method for position-selective labeling of RNAs

Phylogica and the University of Queensland receive grant for macrocylic phylomer drugs

Saphris sublingual tablets launched in the U.S. for bipolar I disorder in pediatric patients

First-in-human trial of the postexposure tuberculosis vaccine H56:IC31 in healthy adults

MoA studies of potent organo-osmium compound reveal potential new anticancer strategy

Negative modulators of alpha5-containing GABA(A) receptors show rapid antidepressant action

FDA grants orphan drug designation to C2N-8E12 for progressive supranuclear palsy

PhaseRx selects lead program to advance into clinic for orphan liver disease indication

Recro Pharma reports positive phase II data for Dex-IN in postsurgical pain

Altamira Bio acquires NIH license and CRADAs for ManNAc

ETC-159 begins phase I study in Singapore for advanced solid tumors

Merck & Co. discloses ERK2 inhibitors

Asana BioSciences presents P2X3 and/or P2X2/3 antagonists

Gilead patents MAP3K5 inhibitors

Calitor introduces JAK inhibitors

ArmaGen opens enrollment in phase I study of AGT-181 for MPS I

Bayer initiates phase I trial of BAY-1143269 with docetaxel for advanced solid tumors

Purdue Pharma patents morphinan analogs

Aquinnah Pharmaceuticals receives ALS Association funding to target TDP-43

Viekira Pak receives FDA orphan drug designation for hepatitis C in pediatric patients

Anti-MMP-9 MAb wins U.S. orphan drug designation for gastric cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.